Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial ModificationGlobeNewsWire • 06/24/24
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and SulindacGlobeNewsWire • 05/06/24
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease WeekGlobeNewsWire • 04/30/24
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025GlobeNewsWire • 04/22/24
Panbela Announces Poster Presentation at American Association for Cancer Research:GlobeNewsWire • 04/18/24
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial ResultsGlobeNewsWire • 03/26/24
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024GlobeNewsWire • 03/12/24
Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)Benzinga • 02/23/24
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares RequirementsGlobeNewsWire • 02/15/24
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)GlobeNewsWire • 01/30/24
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated MomentumGlobeNewsWire • 01/25/24
Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy TrialGlobeNewsWire • 01/18/24
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-MarketGlobeNewsWire • 12/21/23